A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs SGN CD70A (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Seattle Genetics
- 09 Jan 2019 Results (n=18) published in the Cancer.
- 22 Aug 2018 Results (n=20) published in the Investigational New Drugs.
- 22 Aug 2018 Status changed from discontinued to completed, according to results published in the Investigational New Drugs.